Invivyd’s (IVVD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report issued on Wednesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, March 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Price Performance

Invivyd stock opened at $0.60 on Wednesday. The company has a market cap of $71.98 million, a PE ratio of -0.31 and a beta of 0.09. Invivyd has a 12 month low of $0.35 and a 12 month high of $4.74. The company has a fifty day moving average price of $1.00 and a two-hundred day moving average price of $0.86.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. Equities research analysts anticipate that Invivyd will post -1.64 earnings per share for the current year.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 86,545 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the transaction, the director now directly owns 3,170,231 shares in the company, valued at $1,521,710.88. This trade represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 17.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Invivyd

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC raised its stake in shares of Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after buying an additional 9,207 shares in the last quarter. State Street Corp lifted its holdings in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Jane Street Group LLC lifted its holdings in Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Invivyd during the 4th quarter valued at about $74,000. Finally, Two Sigma Investments LP grew its stake in shares of Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after purchasing an additional 204,188 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.